How I treat older patients with Ph/BCR-ABL–negative acute lymphoblastic leukemia

2.

Huguet

F

,

Chevret

S

,

Leguay

T

, et al.

Intensified therapy of acute lymphoblastic leukemia in adults: report of the Randomized GRAALL-2005 Clinical Trial

.

J Clin Oncol

.

2018

;

36

(

24

):

2514

-

2523

.

3.

Gokbuget

N

.

How should we treat a patient with relapsed Ph-negative B-ALL and what novel approaches are being investigated?

.

Best Pract Res Clin Haematol

.

2017

;

30

(

3

):

261

-

274

.

4.

Goekbuget

N

,

Viardot

A

,

Steffen

B

, et al.

Outcome of 841 older patients (>55 yrs) with newly diagnosed Ph/BCR-ABL negative ALL prospectively treated according to pediatric-based, age-adapted GMALL protocols

.

Blood

.

2022

;

140

(

suppl 1

):

121

-

123

.

5.

Gokbuget

N

.

How I treat older patients with ALL

.

Blood

.

2013

;

122

(

8

):

1366

-

1375

.

6.

Moorman

AV

,

Chilton

L

,

Wilkinson

J

,

Ensor

HM

,

Bown

N

,

Proctor

SJ

.

A population-based cytogenetic study of adults with acute lymphoblastic leukemia

.

Blood

.

2010

;

115

(

2

):

206

-

214

.

7.

Creasey

T

,

Barretta

E

,

Ryan

SL

, et al.

Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials

.

Haematologica

.

2022

;

107

(

9

):

2051

-

2063

.

8.

Stengel

A

,

Schnittger

S

,

Weissmann

S

, et al.

TP53 mutations occur in 15.7% of ALL and are associated with MYC-rearrangement, low hypodiploidy, and a poor prognosis

.

Blood

.

2014

;

124

(

2

):

251

-

258

.

9.

Chiaretti

S

,

Vitale

A

,

Cazzaniga

G

, et al.

Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts

.

Haematologica

.

2013

;

98

(

11

):

1702

-

1710

.

10.

Roberts

KG

,

Li

Y

,

Payne-Turner

D

, et al.

Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia

.

N Engl J Med

.

2014

;

371

(

11

):

1005

-

1015

.

11.

Herold

T

,

Schneider

S

,

Metzeler

KH

, et al.

Adults with Philadelphia chromosome-like acute lymphoblastic leukemia frequently have IGH-CRLF2 and JAK2 mutations, persistence of minimal residual disease and poor prognosis

.

Haematologica

.

2017

;

102

(

1

):

130

-

138

.

12.

Herold

T

,

Baldus

CD

,

Gokbuget

N

.

Ph-like acute lymphoblastic leukemia in older adults

.

N Engl J Med

.

2014

;

371

(

23

):

2235

.

13.

Giri

S

,

Chi

M

,

Johnson

B

, et al.

Secondary acute lymphoblastic leukemia is an independent predictor of poor prognosis

.

Leuk Res

.

2015

;

39

(

12

):

1342

-

1346

.

14.

Abdel Rahman

ZH

,

Parrondo

RD

,

Heckman

MG

, et al.

Comparative study of therapy-related and de novo adult b-cell acute lymphoblastic leukaemia

.

Br J Haematol

.

2022

;

196

(

4

):

963

-

968

.

15.

Furstenau

M

,

Fink

AM

,

Schilhabel

A

, et al.

B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

.

Blood

.

2021

;

137

(

16

):

2267

-

2271

.

16.

Germans

SK

,

Kulak

O

,

Koduru

P

, et al.

Lenalidomide-associated secondary B-lymphoblastic leukemia/lymphoma-a unique entity

.

Am J Clin Pathol

.

2020

;

154

(

6

):

816

-

827

.

17.

Saygin

C

,

Kishtagari

A

,

Cassaday

RD

, et al.

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

.

Blood Adv

.

2019

;

3

(

24

):

4228

-

4237

.

18.

Khan

M

,

Siddiqi

R

,

Naqvi

K

.

An update on classification, genetics, and clinical approach to mixed phenotype acute leukemia (MPAL)

.

Ann Hematol

.

2018

;

97

(

6

):

945

-

953

.

19.

Wolach

O

,

Stone

RM

.

Mixed-phenotype acute leukemia: current challenges in diagnosis and therapy

.

Curr Opin Hematol

.

2017

;

24

(

2

):

139

-

145

.

20.

Orgel

E

,

Alexander

TB

,

Wood

BL

, et al.

Mixed-phenotype acute leukemia: a cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force

.

Cancer

.

2020

;

126

(

3

):

593

-

601

.

21.

Takahashi

K

,

Wang

F

,

Kantarjian

H

, et al.

Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study

.

Lancet Oncol

.

2017

;

18

(

1

):

100

-

111

.

22.

Saygin

C

,

Zhang

P

,

Stauber

J

, et al.

Acute lymphoblastic leukemia with myeloid mutations is a high-risk disease associated with clonal hematopoiesis

.

Blood Cancer Discov

.

2024

;

5

(

3

):

164

-

179

.

23.

Jabbour

E

,

Short

NJ

,

Senapati

J

, et al.

Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial

.

Lancet Haematol

.

2023

;

10

(

6

):

e433

-

e444

.

24.

Wermann

WK

,

Viardot

A

,

Kayser

S

, et al.

Comorbidities are frequent in older patients with de novo acute lymphoblastic leukemia (ALL) and correlate with induction mortality: analysis of more than 1200 patients from GMALL Data Bases

.

Blood

.

2018

;

132

(

suppl 1

):

660

.

25.

Magnuson

A

,

Sattar

S

,

Nightingale

G

,

Saracino

R

,

Skonecki

E

,

Trevino

KM

.

A practical guide to geriatric syndromes in older adults with cancer: a focus on falls, cognition, polypharmacy, and depression

.

Am Soc Clin Oncol Educ Book

.

2019

;

39

:

e96

-

e109

.

26.

Mohile

SG

,

Dale

W

,

Somerfield

MR

, et al.

Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO Guideline for Geriatric Oncology

.

J Clin Oncol

.

2018

;

36

(

22

):

2326

-

2347

.

27.

Wildiers

H

,

Heeren

P

,

Puts

M

, et al.

International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer

.

J Clin Oncol

.

2014

;

32

(

24

):

2595

-

2603

.

28.

Gokbuget

N

,

Boissel

N

,

Chiaretti

S

, et al.

Diagnosis, prognostic factors and assessment of ALL in adults: 2023 ELN recommendations from a European Expert Panel

.

Blood

.

2024

;

143

(

19

):

1903

-

1930

.

29.

Goekbuget

N

,

Beck

J

,

Brueggemann

M

, et al.

Moderate intensive chemotherapy including CNS-prophylaxis with liposomal cytarabine is feasible and effective in older patients with Ph-negative acute lymphoblastic leukemia (ALL): results of a Prospective Trial From the German Multicenter Study Group for Adult ALL (GMALL)

.

Blood

.

2012

;

120

(

21

):

1493

.

30.

van Dongen

JJ

,

van der Velden

VH

,

Bruggemann

M

,

Orfao

A

.

Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies

.

Blood

.

2015

;

125

(

26

):

3996

-

4009

.

31.

Gokbuget

N

,

Kneba

M

,

Raff

T

, et al.

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

.

Blood

.

2012

;

120

(

9

):

1868

-

1876

.

32.

Short

NJ

,

Kantarjian

H

,

Ravandi

F

, et al.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

.

Blood Adv

.

2022

;

6

(

13

):

4006

-

4014

.

33.

Kotrova

M

,

Koopmann

J

,

Trautmann

H

, et al.

Prognostic value of low-level MRD in adult acute lymphoblastic leukemia detected by low- and high-throughput methods

.

Blood Adv

.

2022

;

6

(

10

):

3006

-

3010

.

34.

Altekruse

SF

,

Kosary

CL

,

Krapcho

M

, et al.

Seer Cancer Statistics Review 1975-2007. National Cancer Institute

. Accessed 5 November 2024. https://seer.cancer.gov/archive/csr/1975_2007/.

35.

Juliusson

G

,

Karlsson

K

,

Hallbook

H

.

Population-based analyses in adult acute lymphoblastic leukemia

.

Blood

.

2010

;

116

(

6

):

1011

-

1012

. author reply 1012.

36.

Toft

N

,

Schmiegelow

K

,

Klausen

TW

,

Birgens

H

.

Adult acute lymphoblastic leukaemia in Denmark. A national population-based retrospective study on acute lymphoblastic leukaemia in Denmark 1998-2008

.

Br J Haematol

.

2012

;

157

(

1

):

97

-

104

.

37.

Kozlowski

P

,

Lennmyr

E

,

Ahlberg

L

, et al.

Age but not Philadelphia positivity impairs outcome in older/elderly patients with acute lymphoblastic leukemia in Sweden

.

Eur J Haematol

.

2017

;

99

(

2

):

141

-

149

.

38.

Dinmohamed

AG

,

Szabo

A

,

van der Mark

M

, et al.

Improved survival in adult patients with acute lymphoblastic leukemia in the Netherlands: a population-based study on treatment, trial participation and survival

.

Leukemia

.

2016

;

30

(

2

):

310

-

317

.

39.

Guru Murthy

GS

,

Venkitachalam

R

,

Mehta

P

.

Trends in survival outcomes of B-lineage acute lymphoblastic leukemia in elderly patients: analysis of Surveillance, Epidemiology, and End Results database

.

Leuk Lymphoma

.

2015

;

56

(

8

):

2296

-

2300

.

40.

Legrand

O

,

Marie

JP

,

Marjanovic

Z

, et al.

Prognostic factors in elderly acute lymphoblastic leukaemia

.

Br J Haematol

.

1997

;

97

(

3

):

596

-

602

.

41.

Pagano

L

,

Mele

L

,

Casorelli

I

,

Fianchi

L

,

Di Febo

A

,

Leone

G

.

Acute lymphoblastic leukemia in the elderly. A twelve-year retrospective, single center study

.

Haematologica

.

2000

;

85

(

12

):

1327

-

1329

.

42.

Ferrari

A

,

Annino

L

,

Crescenzi

S

,

Romani

C

,

Mandelli

F

.

Acute lymphoblastic leukemia in the elderly: results of two different treatment approaches in 49 patients during a 25-year period

.

Leukemia

.

1995

;

9

(

10

):

1643

-

1647

.

43.

Taylor

PR

,

Reid

MM

,

Proctor

SJ

.

Acute lymphoblastic leukaemia in the elderly

.

Leuk Lymphoma

.

1994

;

13

(

5-6

):

373

-

380

.

44.

Hunault-Berger

M

,

Leguay

T

,

Thomas

X

, et al.

A randomized study of pegylated liposomal doxorubicin versus continuous-infusion doxorubicin in elderly patients with acute lymphoblastic leukemia: the GRAALL-SA1 study

.

Haematologica

.

2011

;

96

(

2

):

245

-

252

.

45.

Ribera

JM

,

Garcia

O

,

Oriol

A

, et al.

Feasibility and results of subtype-oriented protocols in older adults and fit elderly patients with acute lymphoblastic leukemia: results of three prospective parallel trials from the PETHEMA group

.

Leuk Res

.

2016

;

41

:

12

-

20

.

46.

Jabbour

E

,

Short

NJ

,

Jain

N

, et al.

The evolution of acute lymphoblastic leukemia research and therapy at MD Anderson over four decades

.

J Hematol Oncol

.

2023

;

16

(

1

):

22

.

47.

Stelljes

M

,

Raffel

S

,

Alakel

N

, et al.

Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL

.

J Clin Oncol

.

2024

;

42

(

3

):

273

-

282

.

48.

Chevallier

P

,

Leguay

T

,

Kim

R

, et al.

Fractionated inotuzumab ozogamicin combined with low-intensity chemotherapy in older patients with newly diagnosed CD22+ Philadelphia chromosome (Ph)-negative B-cell precursor (BCP) acute lymphoblastic leukemia (ALL): results of the EWALL-INO Study

.

Blood

.

2022

;

140

(

suppl 1

):

6114

-

6116

.

49.

Goekbuget

N

,

Schwartz

S

,

Faul

C

, et al.

Dose reduced chemotherapy in sequence with blinatumomab for newly diagnosed older patients with Ph/BCR::ABL negative B-precursor adult lymphoblastic leukemia (ALL): preliminary results of the GMALL BOLD Trial

.

Blood

.

2023

;

142

(

suppl 1

):

964

.

50.

Advani

AS

,

Moseley

A

,

O'Dwyer

KM

, et al.

SWOG 1318: a phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia

.

J Clin Oncol

.

2022

;

40

(

14

):

1574

-

1582

.

51.

Wieduwilt

M

,

Yin

J

,

Kour

O

, et al.

Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly-diagnosed, PH-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703

.

Hemasphere

.

2023

;

7

(

suppl 3

):

41

-

42

.

52.

Aapro

M

,

Bernard-Marty

C

,

Brain

EG

, et al.

Anthracycline cardiotoxicity in the elderly cancer patient: a SIOG expert position paper

.

Ann Oncol

.

2011

;

22

(

2

):

257

-

267

.

53.

Bassan

R

,

Di Bona

E

,

Lerede

T

, et al.

Age-adapted moderate-dose induction and flexible outpatient postremission therapy for elderly patients with acute lymphoblastic leukemia

.

LeukLymphoma

.

1996

;

22

(

3-4

):

295

-

301

.

54.

Offidani

M

,

Corvatta

L

,

Malerba

L

, et al.

Comparison of two regimens for the treatment of elderly patients with acute lymphoblastic leukaemia (ALL)

.

Leuk Lymphoma

.

2005

;

46

(

2

):

233

-

238

.

55.

Chow

EJ

,

Aggarwal

S

,

Doody

DR

, et al.

Dexrazoxane and long-term heart function in survivors of childhood cancer

.

J Clin Oncol

.

2023

;

41

(

12

):

2248

-

2257

.

56.

Sancho

JM

,

Ribera

JM

,

Xicoy

B

, et al.

Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia

.

Eur J Haematol

.

2007

;

78

(

2

):

102

-

110

.

57.

Patel

B

,

Kirkwood

AA

,

Dey

A

, et al.

Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial

.

Leukemia

.

2017

;

31

(

1

):

58

-

64

.

58.

Rausch

CR

,

Jabbour

EJ

,

Kantarjian

HM

,

Kadia

TM

.

Optimizing the use of the hyperCVAD regimen: clinical vignettes and practical management

.

Cancer

.

2020

;

126

(

6

):

1152

-

1160

.

59.

Thomas

DA

,

O'Brien

S

,

Faderl

S

, et al.

Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia

.

J Clin Oncol

.

2010

;

28

(

24

):

3880

-

3889

.

60.

Gökbuget

N

,

Hartog

MC

,

Dengler

J

, et al.

First analysis of prognostic factors in elderly Ph/BCR-ABL negative ALL including comorbidity scores: different factors predict mortality and relapse

.

Onkologie

.

2008

;

31

(

suppl 4

):

14(V29)

.

61.

Kantarjian

HM

,

Stein

AS

,

Bargou

RC

, et al.

Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies

.

Cancer

.

2016

;

122

(

14

):

2178

-

2185

.

62.

Kantarjian

HM

,

DeAngelo

DJ

,

Stelljes

M

, et al.

Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia

.

N Engl J Med

.

2016

;

375

(

8

):

740

-

753

.

63.

Dombret

H

,

Topp

MS

,

Schuh

AC

, et al.

Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia

.

Leuk Lymphoma

.

2019

;

60

(

9

):

2214

-

2222

.

64.

Topp

MS

,

Gokbuget

N

,

Zugmaier

G

, et al.

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

.

Blood

.

2012

;

120

(

26

):

5185

-

5187

.

65.

Topp

MS

,

Kufer

P

,

Gökbuget

N

, et al.

Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival

.

J Clin Oncol

.

2011

;

29

(

18

):

2493

-

2498

.

66.

Gokbuget

N

,

Dombret

H

,

Bonifacio

M

, et al.

Blinatumomab for minimal residual disease in adults with B-precursor acute lymphoblastic leukemia

.

Blood

.

2018

;

131

(

14

):

1522

-

1531

.

67.

Gokbuget

N

,

Zugmaier

G

,

Dombret

H

, et al.

Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia

.

Leuk Lymphoma

.

2020

;

61

(

11

):

2665

-

2673

.

68.

Jabbour

E

,

Haddad

FG

,

Short

NJ

, et al.

Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission

.

Blood

.

2024

;

143

(

5

):

417

-

421

.

69.

Litzow

MR

,

Sun

Z

,

Mattison

RJ

, et al.

Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults

.

N Engl J Med

.

2024

;

391

(

4

):

320

-

333

.

70.

Kantarjian

H

,

Ravandi

F

,

Short

NJ

, et al.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study

.

Lancet Oncol

.

2018

;

19

(

2

):

240

-

248

.

71.

Jabbour

EJ

,

Sasaki

K

,

Ravandi

F

, et al.

Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis

.

Cancer

.

2019

;

125

(

15

):

2579

-

2586

.

72.

Stelljes

M

,

Raffel

S

,

Alakel

N

, et al.

Inotuzumab ozogamicin as induction therapy for patients older than 55 years with Philadelphia chromosome-negative B-precursor ALL

.

J Clin Oncol

.

2023

;

42

(

3

):

273

-

282

.

73.

Jabbour

E

,

Aldoss

I

,

Fleming

S

, et al.

Blinatumomab alternating with low-intensity chemotherapy (CT) treatment for older adults with newly diagnosed Philadelphia (Ph)-negative B-cell precursor acute lymphoblastic leukemia (BCPALL) is well tolerated and efficacious: safety run-in results for the phase 3 randomized controlled Golden Gate Study

.

Blood

.

2022

;

140

(

suppl 1

):

6134

-

6136

.

74.

Ribera

JM

,

Garcia

O

,

Chapchap

EC

, et al.

Treatment of frail older adults and elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: results of a prospective trial with minimal chemotherapy

.

Clin Lymphoma Myeloma Leuk

.

2020

;

20

(

8

):

e513

-

e522

.

75.

Candoni

A

,

Coppola

G

.

A 2024 update on menin inhibitors. A new class of target agents against KMT2A-rearranged and NPM1-mutated acute myeloid leukemia

.

Hematol Rep

.

2024

;

16

(

2

):

244

-

254

.

76.

Pasvolsky

O

,

Kebriaei

P

,

Shah

BD

,

Jabbour

E

,

Jain

N

.

Chimeric antigen receptor T-cell therapy for adult B-cell acute lymphoblastic leukemia: state-of-the-(C)ART and the road ahead

.

Blood Adv

.

2023

;

7

(

14

):

3350

-

3360

.

77.

Shouse

G

,

Danilov

AV

,

Artz

A

.

CAR T-cell therapy in the older person: indications and risks

.

Curr Oncol Rep

.

2022

;

24

(

9

):

1189

-

1199

.

78.

Bug

G

,

Labopin

M

,

Niittyvuopio

R

, et al.

Fludarabine/TBI 8 Gy versus fludarabine/treosulfan conditioning in patients with AML in first complete remission: a study from the Acute Leukemia Working Party of the EBMT

.

Bone Marrow Transplant

.

2023

;

58

(

6

):

710

-

716

.

79.

Marks

DI

,

Clifton-Hadley

L

,

Copland

M

, et al.

In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial

.

Lancet Haematol

.

2022

;

9

(

4

):

e276

-

e288

.